secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2026-08-05T20:12:27+00:00
Accession:  0002019410-26-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B
--------------------------------------------------------------------------------

- Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.
- Clinical cases ~59,200 (+18% YoY); gross margin improved 500 bps to 68%.
- Raised 2026 revenue guidance to $1.03-1.04B (27-28% growth); reaffirmed ~20% clinical therapy selection volume growth.
- Launched Caris Detect multi-cancer early detection blood test and Caris ChromoSeq for myeloid malignancies.
- Share repurchase program of up to $100M authorized; $82.1M remains available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/0002019410-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/cai-20260805.htm
  HTML page:      https://secwatch.observer/filing/0002019410-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer